Cosmo Pharmaceuticals: Revolutionizing Healthcare, Transforming Lives

Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) is set to release its unaudited Full-Year 2024 financial results on March 6, 2025, at 7:00 am CET. The company will host a live webcast presentation at 3:00 pm CET on the same day, providing an in-depth overview of its latest financial and operational performance, strategic initiatives, growth opportunities, and future outlook. CEO Giovanni Di Napoli and CFO Svetlana Sigalova will present, followed by a Q&A session.

Cosmo Pharmaceuticals is committed to revolutionizing healthcare and transforming people's lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology, and contract manufacturing & development. The company collaborates with leading partners worldwide, including Medtronic and Sun Pharma, to commercialize and distribute its products.

In 2024, Cosmo Pharmaceuticals reported strong preliminary unaudited revenue and year-end cash, reflecting exceptional revenue growth and a robust cash position. The company's revenue increased to €265.7 million, representing a 186% year-over-year increase from €92.8 million in 2023. This growth was driven by various factors, including the receipt of a €185 million upfront payment from Medtronic linked to the December 2023 expanded agreement and milestones related to the delivery of AI advancements in the GI Genius™ platform. The company's cash position also improved significantly, with year-end cash, equivalents, and short-term investments of €170.4 million, compared to €50.3 million at the end of 2023.

Cosmo Pharmaceuticals' strong financial performance and strategic initiatives have positioned the company for sustained top-line growth. The company's pipeline progress, including advancements in one late-stage and three mid- and early-stage programs, is expected to drive future revenue growth. Key milestones are anticipated in 2025 and 2026, further solidifying Cosmo's position in the healthcare industry.

The upcoming webcast is an excellent opportunity for investors, financial analysts, and business/life sciences journalists to engage directly with Cosmo Pharmaceuticals' leadership team and gain insights into the company's strategic initiatives, growth opportunities, and future outlook. The webcast will be accessible online shortly after the event and available for three months, along with the presentation. The 2024 Annual Report will be available for download on Thursday, 20 March 2025, as of 7:00 am CET at .




In conclusion, Cosmo Pharmaceuticals' strong financial performance, strategic initiatives, and pipeline progress position the company for sustained top-line growth and a promising future in the healthcare industry. The upcoming webcast is an excellent opportunity for stakeholders to engage with the company's leadership team and gain insights into its strategic initiatives, growth opportunities, and future outlook.